Portfolio company Abliva was acquired by Pharming Technologies via a completed cash offer to shareholders.
Abliva develops medicines for the treatment of mitochondrial disease, focusing on improving mitochondrial health through research and development of orphan drugs
Abliva develops medicines for the treatment of mitochondrial disease, focusing on improving mitochondrial health through research and development of orphan drugs.